Mirae Asset Global Investments
RCKT icon

Mirae Asset Global Investments’s Rocket Pharmaceuticals RCKT Stock Holding History

Mirae Asset Global Investments’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7K Sell
4,884
-779
-14% -$2.59K ﹤0.01% 1509
2026
Q1 		$20.3K Buy
5,663
+404
+8% +$1.61K ﹤0.01% 1430
2025
Q4 		$18.5K Buy
5,259
+1,087
+26% +$3.72K ﹤0.01% 1548
2025
Q3 		$13.6K Buy
4,172
+10
+0.2% +$31 ﹤0.01% 1539
2025
Q2 		$10.2K Buy
4,162
+594
+17% +$3.01K ﹤0.01% 1488
2025
Q1 		$27.1K Buy
3,568
+530
+17% +$5.24K ﹤0.01% 1348
2024
Q4 		$35.7K Sell
3,038
-254
-8% -$3.82K ﹤0.01% 1321
2024
Q3 		$60.8K Buy
3,292
+582
+21% +$11.9K ﹤0.01% 1268
2024
Q2 		$58.1K Sell
2,710
-299,122
-99% -$6.87M ﹤0.01% 1217
2024
Q1 		$4.91M Buy
301,832
+129,358
+75% +$3.67M 0.01% 901
2023
Q4 		$5.17M Sell
172,474
-215,230
-56% -$4.75M 0.01% 884
2023
Q3 		$7.94M Buy
387,704
+31,653
+9% +$575K 0.02% 706
2023
Q2 		$7.08M Buy
356,051
+51,534
+17% +$1.04M 0.02% 795
2023
Q1 		$5.22M Buy
304,517
+20,084
+7% +$393K 0.01% 849
2022
Q4 		$5.57M Sell
284,433
-56,963
-17% -$1.05M 0.01% 788
2022
Q3 		$5.45M Buy
341,396
+78,396
+30% +$1.22M 0.01% 771
2022
Q2 		$3.62M Buy
263,000
+21,808
+9% +$260K 0.01% 939
2022
Q1 		$3.83M Sell
241,192
-31,212
-11% -$539K 0.01% 956
2021
Q4 		$5.95M Buy
272,404
+62,896
+30% +$1.72M 0.01% 840
2021
Q3 		$6.26M Buy
209,508
+43,930
+27% +$1.6M 0.02% 778
2021
Q2 		$7.33M Buy
165,578
+29,500
+22% +$1.28M 0.02% 722
2021
Q1 		$6.04M Buy
136,078
+73,124
+116% +$4.02M 0.02% 695
2020
Q4 		$3.45M Buy
62,954
+13,904
+28% +$507K 0.01% 750
2020
Q3 		$1.12M Buy
49,050
+15,824
+48% +$390K 0.01% 932
2020
Q2 		$696K Buy
33,226
+13,591
+69% +$245K ﹤0.01% 1028
2020
Q1 		$274K Buy
19,635
+2,147
+12% +$42.5K ﹤0.01% 1219
2019
Q4 		$398K Buy
17,488
+3,294
+23% +$55K ﹤0.01% 1293
2019
Q3 		$165K Buy
+14,194
New +$176K ﹤0.01% 1389

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Mirae Asset Global Investments's RCKT Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Rocket Pharmaceuticals (RCKT) stake by 14% in Q2 2026, selling an estimated $2.59K and leaving 4,884 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1509.

Mirae Asset Global Investments first reported a position in RCKT in Q3 2019 and has held it in 28 quarters since. The position peaked at $7.94M in Q3 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Mirae Asset Global Investments held 4,884 shares of Rocket Pharmaceuticals worth $16.7K as of Q2 2026.
  • Mirae Asset Global Investments sold 779 Rocket Pharmaceuticals shares in Q2 2026, an estimated $2.59K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1509 holding.
  • Mirae Asset Global Investments first reported a position in Rocket Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • Mirae Asset Global Investments's Rocket Pharmaceuticals position peaked at $7.94M in Q3 2023.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.